Association of Interleukin-18 with Sustained Virological Response (SVR) To Interferon Therapy in Patients with Chronic Liver Diseases

被引:0
|
作者
Mohamed, Waleed S. [1 ]
Loutfy, Samah A. [1 ]
Mohamed, Amal A. [2 ]
Amer, Marwa [3 ]
机构
[1] Cairo Univ, Virol & Immunol Unit, Dept Canc Biol, Natl Canc Inst, Cairo, Egypt
[2] Zagazig Univ, Biochem & Mol Biol Natl Hepatol & Trop Med Res In, Zagazig, Egypt
[3] Zagazig Univ, Chem & Bot Dept, Fac Sci, Zagazig, Egypt
来源
LIFE SCIENCE JOURNAL-ACTA ZHENGZHOU UNIVERSITY OVERSEAS EDITION | 2012年 / 9卷 / 04期
关键词
Hepatitis C virus (HCV); Antiviral therapy (interferon; ribavirin); Interleukin-18 (IL-18); CHRONIC HEPATITIS-C; HEPATOCELLULAR-CARCINOMA; ANTIVIRAL THERAPY; INFECTION; ALPHA; RIBAVIRIN; FIBROSIS; CELLS; IL-18;
D O I
暂无
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Pegylated interferon plus ribavirin is the standard therapy for treatment of Chronic hepatitis C (CHC) patients, this therapy is only effective in 50-60% of infected individuals. Pretreatment predictors associated with sustained virological response (SVR) to interferon treatment have not yet been fully investigated. Several factors have been shown to influence response to antiviral treatment, one of them is interleukin - 18 (IL-18). There are few data on IL-18 in relation to infectious diseases, but it plays a prominent role in chronic HCV infection. Thus, the current study is designated to assess serum Interleukin -18 levels in CHC genotype 4 patients and its association with treatment response. Patients and Methods: This study was performed on fifty Egyptian chronic hepatitis C patients, who received combined pegylated interferon alpha and ribavirin therapy and twenty healthy blood donors as a control group. Quantitative hepatitis C virus RNA was done by real time RT-PCR technique. Serum IL-18 level was assayed using quantitative ELISA plate method. Results: The mean level of IL-18 was significantly higher in CHC patients (212.15 Pg/ml) compared to the controls (48.95 Pg/ml). IL-18 level in responders was significantly reduced after 6 months from the end of treatment compared to those at baseline level (P=0.001), but such decrease was lower than that in non responders (P= 0.058). IL-18 level was positively correlated with high and moderate viral load in non responders. Conclusions: Serum IL-18 level has the potential to be used as a biological marker to predict outcome of antiviral therapy among CHC genotype 4 patients. [Waleed S. Mohamed, Samah A. Loutfy, Amal A. Mohamed and Marwa Amer. Association of Interleukin-18 with Sustained Virological Response (SVR) To Interferon Therapy in Patients with Chronic Liver Diseases. Life Sci J 2012; 9(4): 4542-4550]. (ISSN: 1097-8135). http://www.lifesciencesite.com. 681
引用
收藏
页码:4542 / 4550
页数:9
相关论文
共 50 条
  • [1] α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response
    Tachi, Yoshihiko
    Hirai, Takanori
    Ishizu, Youji
    Honda, Takashi
    Kuzuya, Teiji
    Hayashi, Kazuhiko
    Ishigami, Masatoshi
    Goto, Hidemi
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 (05) : 1001 - 1008
  • [2] The association of cryoglobulinaemia with sustained virological response in patients with chronic hepatitis C
    Vigani, A. G.
    Macedo de Oliveira, A.
    Tozzo, R.
    Pavan, M. H. P.
    Goncales, E. S.
    Fais, V.
    Goncales, N. S.
    Goncales, F. L.
    JOURNAL OF VIRAL HEPATITIS, 2011, 18 (04) : e91 - e98
  • [3] Liver stiffness reduction correlates with histological characteristics of hepatitis C patients with sustained virological response
    Tachi, Yoshihiko
    Hirai, Takanori
    Kojima, Yuko
    Ishizu, Yoji
    Honda, Takashi
    Kuzuya, Teiji
    Hayashi, Kazuhiko
    Ishigami, Masatoshi
    Goto, Hidemi
    LIVER INTERNATIONAL, 2018, 38 (01) : 59 - 67
  • [4] Treatment of chronic hepatitis C regiments containing with recombinant interferon in patients with sustained virological response predicts risk of hepatocellular carcinoma A meta-analysis
    Li, Chien-Feng
    Tsao, Shih-Ming
    Liao, Hsien-Hua
    Chen, Shiuan-Chih
    Lee, Yuan-Ti
    MEDICINE, 2020, 99 (40) : E22435
  • [5] A histological response to antiviral therapy for chronic hepatitis C in patients who failed to achieve a sustained virological response
    Ryumin, A. M.
    Korochkina, O. V.
    TERAPEVTICHESKII ARKHIV, 2012, 84 (11) : 59 - 60
  • [6] Favorable Prognosis in Patients with Sustained Virological Response to Antiviral Therapy, Including Interferon, for Chronic Hepatitis C Before Hepatic Resection for Hepatocellular Carcinoma
    Shirabe, Ken
    Sugimachi, Keishi
    Harada, Noboru
    Kayashima, Hiroto
    Maeda, Takashi
    Tsujita, Eiji
    Minagawa, Ryosuke
    Kajiyama, Kiyoshi
    Yoshiya, Shohei
    Maehara, Yoshihiko
    ANTICANCER RESEARCH, 2015, 35 (12) : 6963 - 6969
  • [7] Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes
    Yamashita, Naoki
    Ohho, Aritsune
    Yamasaki, Akihiro
    Kurokawa, Miho
    Kotoh, Kazuhiro
    Kajiwara, Eiji
    JOURNAL OF GASTROENTEROLOGY, 2014, 49 (11) : 1504 - 1513
  • [8] Significance of hepatic resection for hepatocellular carcinoma with sustained virological response to interferon therapy for chronic hepatitis C
    Sugimachi, Keishi
    Kinjo, Nao
    Ikebe, Masahiko
    Yamashita, Naoki
    Kajiwara, Eiji
    Mimori, Koshi
    Higashi, Hidefumi
    HEPATOLOGY RESEARCH, 2013, 43 (06) : 605 - 609
  • [9] Comparison of postoperative outcomes in cases achieving sustained virological response with direct-acting antiviral and interferon therapy
    Hashimoto, Masakazu
    Kobayashi, Tsuyoshi
    Ohira, Masahiro
    Okimoto, Sho
    Abe, Tomoyuki
    Inoue, Masashi
    Onoe, Takashi
    Honmyo, Naruhiko
    Kuroda, Shintaro
    Ohdan, Hideki
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2024, 31 (05) : 318 - 328
  • [10] Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin
    Namikawa, Masashi
    Kakizaki, Satoru
    Yata, Yutaka
    Yamazaki, Yuichi
    Horiguchi, Norio
    Sato, Ken
    Takagi, Hitoshi
    Mori, Masatomo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 (01) : 69 - 75